Page last updated: 2024-11-10

3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol: (-)-CP-55,940 and (+)-CP-56,667 are enantiomers; RN refers to CP-55,940 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4412255
CHEMBL ID77520
CHEBI ID91490
SCHEMBL ID563759
MeSH IDM0154194

Synonyms (31)

Synonym
CHEMBL77520
HMS3267G11
cp 55940
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol
5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol
L000004
2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
A840483
5-(2-methyloctan-2-yl)-2-[5-oxidanyl-2-(3-oxidanylpropyl)cyclohexyl]phenol
83002-04-4
FT-0641893
(-)-cp 55940
BRD-A03816571-001-01-0
cp-55,667
cp55,667
HMS3372L18
gtpl5570
cp 55,667
SCHEMBL563759
YNZFFALZMRAPHQ-UHFFFAOYSA-N
(+)-cp 55,940
CHEBI:91490
us9339486, cp55,940
bdbm227552
(-)-3-[2-hydroxy-4-(1,1-dimethylheptyl)-phenyl]-4-[3-hydroxypropyl]cyclohexan-1-ol
BCP21009
cp 55940; cp55940; cp-55940;cp-55,667; cp 55667; cp-55667
Q5013768
((c)i)-cp 55,940
Q27076898
(-)-cp55940;(-)-cp-55940

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Either protective or toxic effects of cannabinoids on cell survival have been reported extensively in the literature; however, the factors that determine the direction of the effect are still obscured."( Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro.
Bologov, A; Gafni, M; Keren, O; Sarne, Y, 2011
)
0.37
" These findings support a neuroprotective and modulatory role of cannabinoids in the early toxic events elicited by agents inducing excitotoxic processes."( Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain.
Castellanos, P; Colín-González, AL; Paz-Loyola, AL; Pinzón, E; Rangel-López, E; Santamaría, A; Serratos, IN; Souza, DO; Torres, I; Wajner, M, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" Beside pharmacokinetic differences, these data therefore denote distinct pharmacodynamic profiles for HU 210 and CP 55,940."( Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodynamic differences between cannabinoid agonists.
Bosier, B; Hermans, E; Lambert, DM; Michotte, Y; Sarre, S; Smolders, I, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" Additional experiments examined these compounds in combination with morphine."( Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice.
Dykstra, LA; Miller, LL; Picker, MJ; Schmidt, KT; Umberger, MD, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves were steep and monotonic, the onset was rapid, and the effect lasted about an hour at the highest dose."( Antinociceptive actions of cannabinoids following intraventricular administration in rats.
Lai, NK; Martin, WJ; Patrick, SL; Tsou, K; Walker, JM, 1993
)
0.29
" Following training, substitution tests using a cumulative dosing procedure revealed that anandamide (0."( (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure.
Burkey, RT; Nation, JR, 1997
)
0.3
" Dose-response curves to (+)-WIN 55212 and CP 55940 were shifted to the right, with no reduction of maximal response, by pretreatment with SR141716A (31."( Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus.
Coutts, AA; Pertwee, RG, 1997
)
0.3
" Treatment of Chinese hamster ovary (CHO) cells expressing the cannabinoid CB1 receptor with the cannabinoid CP 55,940, {(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hyd roxypropyl) cyclohexan-1-ol} resulted in cyclic AMP accumulation in a dose-response manner, an accumulation blocked by the cannabinoid CB1 receptor-specific antagonist SR 141716A, {N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-me thyl-1H-pyrazole-3-carboxamide hydrochloride}."( Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.
Calandra, B; Carillon, C; Delpech, M; Ferrara, P; Kernéis, A; Le Fur, G; Portier, M; Shire, D, 1999
)
0.3
" Administration of the D(1) antagonist SCH23390 enhanced the effects of levonantradol, producing a leftward shift of the log dose-response curve."( Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity.
Conley, TJ; Howlett, AC; Meschler, JP, 2000
)
0.31
" Transdermal delivery is a convenient and desirable dosage form for these drugs and health conditions."( Transdermal permeation of WIN 55,212-2 and CP 55,940 in human skin in vitro.
Hammell, DC; Kiptoo, PK; Stinchcomb, AL; Valiveti, S, 2004
)
0.32
"Startle responses were measured in 64 male Wistar rats while varying startling stimulus intensities, analogous to dose-response curves."( Corticosteroid dependent and independent effects of a cannabinoid agonist on core temperature, motor activity, and prepulse inhibition of the acoustic startle reflex in Wistar rats.
Avdesh, A; Cornelisse, V; Martin-Iverson, MT, 2012
)
0.38
" With the most commonly observed defects involving the eyes, the incidence and severity of readily identifiable ocular malformations were utilized as a basis for dose-response analyses."( Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice.
Baker, LK; Dehart, DB; Fish, EW; Gilbert, MT; Parnell, SE; Sulik, KK,
)
0.13
" Although the FAAH inhibitors PF-3845 ((N-3-pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide) and URB597 (cyclohexylcarbamic acid 3'-(aminocarbonyl)-[1,1'-biphenyl]-3-yl ester) did not substitute for SA-57, PF-3845 produced a 2-fold leftward shift in the MJN110 substitution dose-response curve."( Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.
Beardsley, PM; Cravatt, BF; Ignatowska-Jankowska, B; Jali, A; Lichtman, AH; Mustafa, M; Niphakis, MJ; Owens, RA; Selley, DE; Wiley, JL, 2016
)
0.43
" Cumulative dose-response functions were determined in eight male Sprague-Dawley rats for spiradoline (0."( Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.
Dahal, S; France, CP; Minervini, V, 2017
)
0.46
" CP55940 induced apoptotic cell death in Jurkat cells, but not in PBL, in a dose-response manner with increasing fragmentation of DNA, arrest of cell cycle and damage of ΔΨm."( Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H
Fox, JE; Jimenez-Del-Rio, M; Mendivil-Perez, M; Soto-Mercado, V; Velez-Pardo, C, 2020
)
0.56
"3 mg/kg) produced the same degree of rightward shift in the dose-response curves for heroin- and THC-induced antinociception, respectively."( Functional consequences of short-term exposure to opioids versus cannabinoids in nonhuman primates.
Ding, H; Kiguchi, N; Kishioka, S; Ko, MC; Mabry, KM, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interferon gamma precursorHomo sapiens (human)AC5013.17500.128015.173038.6100AID1259418; AID1259420
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID493017Wombat Data for BeliefDocking2000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2011The Journal of pharmacology and experimental therapeutics, Apr, Volume: 337, Issue:1
Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (699)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (0.43)18.7374
1990's198 (28.33)18.2507
2000's295 (42.20)29.6817
2010's181 (25.89)24.3611
2020's22 (3.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.34 (24.57)
Research Supply Index6.57 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (0.98%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other704 (99.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]